Difference between revisions of "Non-small cell lung cancer, MET-mutated"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 1: | Line 1: | ||
| − | {| class="wikitable" style="text-align:center; width: | + | {| class="wikitable" style="text-align:center; width:100%;" |
| − | !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' | + | ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor''' |
| + | ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Section editor''' | ||
|- | |- | ||
| + | | style="background-color:#F0F0F0; width:15%" |[[File:Amit_Kulkarni.jpg|frameless|upright=0.3|center]] | ||
| + | | style="width:35%" |<big>[[User:Akulkarni|Amit Kulkarni, MBBS]]<br>University of Minnesota<br>Minneapolis, MN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/AmitKulkarniMD AmitKulkarniMD] | ||
|style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|frameless|upright=0.3|center]] | |style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|frameless|upright=0.3|center]] | ||
|<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Vanderbilt University<br>Nashville, TN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn] | |<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Vanderbilt University<br>Nashville, TN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn] | ||
Revision as of 20:10, 6 June 2020
| Page editor | Section editor | ||
|---|---|---|---|
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN  AmitKulkarniMD
|
 |
Travis Osterman, DO, MS Vanderbilt University Nashville, TN TravisOsterman |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Metastatic disease
Capmatinib monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Wolf et al. 2019 (GEOMETRY mono-1) | Phase II (RT) |
Biomarker Eligibility Criteria
- Biomarker: MET exon 14 skipping
Chemotherapy
- Capmatinib (Tabrecta) 400 mg PO twice per day with or without food
Continued indefinitely
References
- Abstract: Juergen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan F. Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Rebecca Suk Heist. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. link to abstract contains verified protocol DOI